Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View


BrainsWay to Report Third Quarter 2021 Financial Results on


GlobeNewswire Inc | Nov 3, 2021 08:00AM EDT

November 03, 2021

BURLINGTON, Mass. and JERUSALEM, Nov. 03, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (BrainsWay or the Company), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its third quarter 2021 financial results as well as operational highlights before the open of the U.S. financial markets onWednesday, November 17, 2021. The Company will host a conference call and webcast at 8:30 AM Eastern Timeto discuss the results and provide an update on business operations.

Conference Call Dial-In & Webcast Information:

Date: Wednesday, November 17, 2021Time: 8:30 AM Eastern TimeUnited States: 877-407-3982International: 201-493-6780Conference ID: 13723993Webcast: http://public.viavid.com/index.php?id=146897

The conference call will be broadcast live and will be available for replay for 30 days on the Companys website, https://investors.brainsway.com/events-and-presentations/event-calendar. Please access the Companys website at least 10 minutes ahead of the conference call to register.

About BrainsWayBrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with offices in Burlington, MA and Jerusalem, Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visitwww.brainsway.com.

Contacts:BrainsWay:Scott Areglado SVP and Chief Financial Officer617-771-2287SAreglado@brainsway.com

Investors:Bob YedidLifeSci Advisors646-597-6989Bob@LifeSciAdvisors.com







Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC